Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen announces positive evolocumab study results

Amgen announces positive evolocumab study results

31st December 2013

Amgen has announced positive results for the DESCARTES (Durable Effect of PCSK9 Antibody Compared With Placebo Study) phase III study of its evolocumab product in people with high cholesterol. 

The 52-week trial monitored the safety, tolerability and efficacy of the treatment on 901 patients with high low-density lipoprotein cholesterol (LDL-C).

Evolcumab was found to significantly reduce the condition, although side effects such as nasopharyngitis, upper respiratory tract infection, influenza and back pain were recorded in less than five per cent of patients.

Sean Harper, Amgen executive vice-president of research and development, stated: "These data contribute to the growing body of research suggesting that evolocumab may offer a new treatment option for patients with dyslipidemia."

Evolcumab is an investigational fully human monoclonal antibody that is used to inhibit proprotein convertase subtilisin/kexin type 9, which affects the liver's ability to extract LDL-C from the blood.

The DESCARTES test is one a of a number planned for the product and follows the Mendel-2 trial, which also yielded positive results.ADNFCR-8000103-ID-801677315-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.